Galectin Therapeutics Inc. (GALT): Price and Financial Metrics
GET POWR RATINGS... FREE!
GALT Stock Price Chart Interactive Chart >
GALT Price/Volume Stats
|Current price||$1.68||52-week high||$3.78|
|Prev. close||$1.66||52-week low||$1.19|
|Day high||$1.68||Avg. volume||95,360|
|50-day MA||$1.92||Dividend yield||N/A|
|200-day MA||$1.77||Market Cap||99.79M|
Galectin Therapeutics Inc. (GALT) Company Bio
Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease and cancer. The company was founded in 2000 and is based in Norcross, Georgia.
Most Popular Stories View All
GALT Latest News Stream
|Loading, please wait...|
GALT Latest Social Stream
View Full GALT Social Stream
Latest GALT News From Around the Web
Below are the latest news stories about GALECTIN THERAPEUTICS INC that investors may wish to consider to help them evaluate GALT as an investment opportunity.
Galectin Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference September 13, 2022
NORCROSS, Ga., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the H.C. Wainwright 24th Annual Global Investment Conference being held on September 12-14, 2022. The Wainwright Conference brings together thought leaders and practitioners from numerous fields to participate in presentations, one-on-one investor meetings, and networking opportunitie
H.C. Wainwright analyst Ed Arce maintained a Buy rating on Galectin Therapeutics (GALT - Research Report) today and set a price target of $11.00. The company's shares closed yesterday at $2.18.According to TipRanks, Arce is a 4-star analyst with an average return of 8.8% and a 40.31% success rate. Arce covers the Healthcare sector, focusing on stocks such as Assembly Biosciences, Pliant Therapeutics, and Galectin Therapeutics.Currently, the analyst consensus on Galectin Therapeutics is a Moderate Buy with an average price target of $11.00.See the top stocks recommended by analysts >>The company has a one-year high of $4.24 and a one-year low of $1.19.
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2022 and Provides Business Update
NORCROSS, Ga., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended June 30, 2022. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the U.S. Securities and Exchange Commission and is available at www.sec.gov. Joel Lewis, Chief Executive Officer and President, sta
Galectin Therapeutics Announces $60 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through 2024
NORCROSS, Ga., July 26, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today it entered into a $60 million unsecured line of credit facility with its chairman and largest individual stockholder, Richard E. Uihlein. “It has been close to fifteen years since I made my first investment in Galectin Therapeutics,” said Richard E. Uihlein, chairman of the board of directors. “While my role in the Company
Galectin Therapeutics Announces 2 Liver Cirrhosis Scientific Presentations at the EASL International Liver Congress™ 2022
NORCROSS, Ga., June 21, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, announced today two scientific presentations regarding the use of artificial intelligence to analyze liver biopsies of patients affected with cirrhosis of the liver due to Nonalcoholic Steatohepatitis (NASH). The data originates from the Company’s phase 2 study (NCT02462967) that evaluated its proprietary drug candidate belapectin in patients w
GALT Price Returns